Genzyme, BioMarin Drug OKd in Europe
- Share via
From Bloomberg News
Genzyme Corp. and BioMarin Pharmaceutical Inc. won European approval of their Aldurazyme treatment for a rare genetic disorder.
The European Commission cleared Aldurazyme for sale in the 15 countries of the European Union to treat patients with the enzyme deficiency called MPS1, the companies said. Aldurazyme won U.S. approval in April.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
